InvestorsHub Logo
Followers 14
Posts 1967
Boards Moderated 0
Alias Born 07/28/2013

Re: None

Thursday, 04/28/2022 3:52:43 PM

Thursday, April 28, 2022 3:52:43 PM

Post# of 3834
New lows on galectin inhibitors might be a result of long time galectin advocate breaking his silence and presenting on emerging growth the possibility of a phase 3 drug candidate on oral and IV form. With a Covid approval could easily go after the markets of the other galectin inhibitors by finding a Covid-19 use case first. So if you love galectin science you gotta sell the others and move into BIXT. EG interview was amazing. Just looks like potential company rotation.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News